The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant buzz within the British Isles, prompting a notable shift in peptide trends. Obtaining these treatments remains a complex landscape, with National Health Service coverage currently limited and private clinics offering treatment at a substantial pric